Trial reportAddiction (Abingdon, England)2025
A heroin overdose laboratory model: How do escalating doses of diamorphine alter respiratory function in a diamorphine-treated population?
Trial report in Addiction (Abingdon, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A heroin overdose laboratory model: How do escalating doses of diamorphine alter respiratory function in a diamorphine-treated population?Addiction (Abingdon, England) · 2025Trial
- From fairytale to clinical practice: A response to commentaries.Addiction (Abingdon, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND &
aimGlobally, more than 100 000 people die annually from opioid overdose. Although strongly implicated in heroin overdose deaths, acute opioid-induced respiratory depression is poorly understood, and few laboratory studies have been completed in human subjects. It is an area of undone science. Using a human laboratory overdose model, our research question was: what is the strength of the association between increasing dose of diamorphine and degree of respiratory depression in people prescribed injectable diamorphine for heroin use disorder?
designSingle-blind, Phase IV, non-randomised, dose-escalation clinical trial.
settingKing's Clinical Research Facility, London, UK.
participantsFour participants prescribed injectable diamorphine as treatment for heroin use disorder [all male, median (range) age 63 (59-72)].
interventionsThe following dosing schedule was implemented (as a % of participant's usual prescribed diamorphine dose): visit 1-100%; visit 2-110%; visit 3-120%; visit 4-100%. Usual dose: 97.5 mg (30 mg-200 mg). MEASUREMENTS: Physiological measures included: pulse oximetry (SpO
findingsRespiratory measures from baseline to post-dose across all dose sessions had ranges of: 89.7%-99.5% SpO
conclusionsA dose-escalation clinical trial of people prescribed injectable diamorphine for heroin addiction found that the degree of respiratory depression caused by diamorphine does not appear to be dose dependent; however, the changes seen at diamorphine doses to which participants were accustomed suggest that participants had only partial tolerance to the respiratory depressant effect of diamorphine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.